Brought to you by 
Epigenomics licenses colorectal cancer biomarker to Abbott
11 May 2010
Executive Summary
Epigenomics AG (molecular diagnostics for cancer) licensed Abbott Molecular nonexclusive global rights to its DNA methylation biomarker Septin9, as well as the option to evaluate some of its other cancer biomarkers.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epigenomics licenses colorectal cancer biomarker to Abbott
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice